Cargando…

Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients

Detalles Bibliográficos
Autores principales:	Aqeel, Faten, Geetha, Duvuru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419428/ https://www.ncbi.nlm.nih.gov/pubmed/36060620 http://dx.doi.org/10.1016/j.ekir.2022.08.019

Ejemplares similares

Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
por: Chen, Benjamin, et al.
Publicado: (2023)

Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies
por: Ocon, Anthony J., et al.
Publicado: (2022)

Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti–neutrophil cytoplasmic antibody–associated vasculitis
por: Kant, Sam, et al.
Publicado: (2022)

Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab
por: Sciascia, Savino, et al.
Publicado: (2023)

Bamlanivimab Decreases Severe Outcomes of SARS-CoV-2 Infection in Patients With Antineutrophil Cytoplasmic Antibody Vasculitis
por: Ghosh, Jyotsna, et al.
Publicado: (2021)

P1574: EFFICACY AND SAFETY OF TIXAGEVIMAB AND CILGAVIMAB (EVUSHELD) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Aleshina (Gavrilina), Olga, et al.
Publicado: (2023)

Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti–neutrophil cytoplasmic antibody vasculitis
por: Kant, Sam, et al.
Publicado: (2021)

Characteristics and Outcomes of COVID-19 in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Kant, Sam, et al.
Publicado: (2020)

Tixagevimab and Cilgavimab (Evusheld – AstraZeneca) efficacy in preventing COVID infection in immunocompromised patients
por: Miot, Christelle, et al.
Publicado: (2023)

Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-Cov-2 in Patients with Multiple Sclerosis on B-Cell Depleters
por: Conte, William L., et al.
Publicado: (2023)

Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients
por: Nguyen, Yann, et al.
Publicado: (2022)

‘Real-World’ Impact of Tixagevimab/Cilgavimab (Evusheld) on COVID-19 Outcomes in Patients Undergoing Cellular Therapies
por: Sannareddy, Aishwarya, et al.
Publicado: (2023)

P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, I., et al.
Publicado: (2023)

Repeat Kidney Biopsies in Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis: Clinical and Histologic Progression
por: Aqeel, Faten, et al.
Publicado: (2023)

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
por: Focosi, Daniele, et al.
Publicado: (2022)

Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters
por: Conte, William L., et al.
Publicado: (2022)

Subcutaneous Immunoglobulin for Antibody Deficiency in Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis
por: Kant, Sam, et al.
Publicado: (2019)

Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Geetha, Duvuru, et al.
Publicado: (2018)

Antineutrophil Cytoplasmic Antibody Vasculitis Causing Skull Base Inflammation and Aortitis
por: Maramattom, Boby Varkey, et al.
Publicado: (2018)

Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study
por: Jakimovski, Dejan, et al.
Publicado: (2023)

(701) Use of Tixagevimab and Cilgavimab (Evusheld) and Subsequent Outcomes of SARS-CoV-2 Infections in Lung Transplant Recipients
por: Grillini, A., et al.
Publicado: (2023)

Practice Patterns of Induction Therapy in Severe Anti-neutrophil Cytoplasmic Autoantibody-Associated Vasculitis
por: Aqeel, Faten, et al.
Publicado: (2022)

Long-term Clinical Course of Antineutrophil Cytoplasmic Antibody-associated Vasculitis Patients off Maintenance Therapy
por: Gapud, Eric J, et al.
Publicado: (2018)

Patient Outcomes in Renal-Limited Antineutrophil Cytoplasmic Antibody Vasculitis With Inactive Histology
por: Novick, Tessa K., et al.
Publicado: (2018)

Tixagevimab + Cilgavimab: First Approval
por: Keam, Susan J.
Publicado: (2022)

SARS-CoV-2 Vaccine Response in Patients With Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
por: Floyd, Lauren, et al.
Publicado: (2021)

The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab–Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center
por: Al-Obaidi, Mohanad M., et al.
Publicado: (2023)

Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study
por: Desai, Aakash, et al.
Publicado: (2023)

Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives
por: Moog, Philipp, et al.
Publicado: (2015)

Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: van Leeuwen, Jolijn R., et al.
Publicado: (2021)

Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis
por: Shah, Shivani, et al.
Publicado: (2017)

Analysis of treatment outcomes in patients with antineutrophil cytoplasmic antibody-associated vasculitis on rituximab therapy
por: Yoneva, Tsvetelina, et al.
Publicado: (2022)

Co-existing proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis with immunoglobulin A nephropathy
por: Kucuk, Adem, et al.
Publicado: (2016)

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
por: Zamprogna, Giulia, et al.
Publicado: (2023)

Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment
por: Vellas, Camille, et al.
Publicado: (2022)

Tixagevimab and cilgavimab for COVID-19 prophylaxis
Publicado: (2022)

The effect of tixagevimab-cilgavimab on clinical outcomes in patients with COVID-19: A systematic review with meta-analysis
por: Wang, Yong, et al.
Publicado: (2023)

Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity
por: Johnson, Sarah, et al.
Publicado: (2023)

Tixagevimab/ Cilgavimab Outcomes Among Patients with Immunodeficiency
por: Sullivan, Juliana
Publicado: (2023)

A case of prolonged COVID‐19 treated with tixagevimab/cilgavimab
por: Shimizu, Takahiro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cete7hh0lu8rk0r2lumvj92su0